Company Interview / Island Pharma progressing in its fight against dengue

Key points:

Island Pharmaceuticals' ISLA-101 targets dengue feverPositive phase 2A trial results enable future therapeutic study$3.5 million funding supports trials and new asset acquisition

Dr David Foster from Island Pharmaceuticals (ASX:ILA) discusses the company's phase 2A clinical trials for ISLA-101, a small molecule drug targeting dengue fever. ISLA-101 shows activity against various viruses like Zika and West Nile. The trial involves pretreating individuals and exposing them to a weakened dengue strain.

David mentions the positive outcome of the trial, confirming antiviral activity. This breakthrough paves the way for a second cohort study set to begin in January 2025, focusing on ISLA-101's potential as a therapeutic treatment.

Island Pharmaceuticals (ASX:ILA) secures $3.5 million to support ongoing and future trials and acquire a new antiviral asset. This funding ensures the company is well-positioned through 2026.